Results of the univariate generalised mixed models with non-responder (yes/no) as dependent variable
| Variable | OR (95% CI) | p Value |
|---|---|---|
| Treatment (bevacizumab vs ranibizumab) | 0.906 (0.445 to 1.845) | 0.78 |
| Vitreous adherences (no vs yes) | 0.361 (0.173 to 0.752) | 0.0075 |
| Fibrosis (no vs yes) | 0.680 (0.317 to 1.459) | 0.32 |
| Haemorrhage* (no vs yes) | 2.599 (0.120 to 56.176) | 0.54 |
| Sex (male vs female) | 0.740 (0.377 to 1.451) | 0.37 |
| Side (right vs left) | 1.164 (0.620 to 2.187) | 0.63 |
| Age | 0.978 (0.945 to 1.012) | 0.19 |
| Lesion (occult vs RAP) | 0.485 (0.201 to 1.174) | 0.11 |
| Lesion (PED vs RAP) | 0.520 (0.222 to 1.218) | 0.13 |
| Lesion (classic vs RAP) | 0.818 (0.244 to 2.740) | 0.74 |
| BCVA baseline | 1.015 (1.005 to 1.027) | 0.0065 |
| OCT baseline | 0.999 (0.995 to 1.002) | 0.44 |
| Number of injections | 1.140 (0.981 to 1.325) | 0.087 |
| Lesion size | 1.043 (0.874 to 1.246) | 0.63 |
*Univariate logistic regression with Firth correction.
BCVA, best corrected visual acuity; OCT, optical coherence tomography; PED, pigment epithelial detachment; RAP, retinal angiomatous proliferation.